How should finerenone be initiated, dosed, and monitored in adults with chronic kidney disease and non‑diabetic proteinuria who are already receiving a maximally tolerated ACE inhibitor or angiotensin receptor blocker?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Finerenone in Non-Diabetic Proteinuria

Current evidence does not support routine use of finerenone in non-diabetic CKD with proteinuria, as the KDIGO 2024 guidelines explicitly recommend nonsteroidal MRAs only for adults with type 2 diabetes and CKD. However, emerging trial data from FIND-CKD suggests potential benefit, creating a gap between guideline recommendations and recent evidence.

Current Guideline Position

The KDIGO 2024 guidelines are clear: finerenone is suggested only for adults with T2D, eGFR >25 ml/min/1.73 m², normal potassium, and albuminuria >30 mg/g despite maximum tolerated RAS inhibitor 1. The guidelines do not extend this recommendation to non-diabetic CKD patients, as the evidence base at the time of publication was limited to diabetic populations.

Key Limitation

The guideline recommendation (3.8.1) carries a 2A grade and explicitly states it applies to "adults with T2D" 1. No parallel recommendation exists for non-diabetic proteinuric CKD in the 2024 KDIGO guidelines.

Emerging Evidence from FIND-CKD Trial

The landscape changed with publication of FIND-CKD (2026), which demonstrated that finerenone slowed eGFR decline by 0.7 ml/min/1.73 m² per year compared to placebo in non-diabetic CKD patients (P<0.001) 2. This trial enrolled 1,584 adults without diabetes who had:

  • eGFR 25 to <90 ml/min/1.73 m²
  • UACR 200 to ≤3,500 mg/g
  • Already receiving a RAS inhibitor

The trial showed a 23% relative risk reduction in the composite kidney/cardiovascular outcome (HR 0.77,95% CI 0.60-0.99) 2. Most participants had chronic glomerulonephritis (57.0%), with IgA nephropathy being the most common specific diagnosis (26.3%) 3.

Clinical Decision Algorithm

If You Choose to Use Finerenone Off-Guideline (Based on FIND-CKD):

Patient Selection Criteria:

  • Non-diabetic CKD with eGFR 25-90 ml/min/1.73 m²
  • UACR ≥200 mg/g (preferably ≥500 mg/g for stronger indication)
  • Already on maximum tolerated ACE inhibitor or ARB
  • Baseline potassium ≤4.8 mmol/L (≤4.8 mEq/L)

Initiation Dosing (per KDIGO algorithm) 1:

Baseline K+ eGFR Starting Dose
≤4.8 mmol/L 25-59 ml/min/1.73 m² 10 mg daily
≤4.8 mmol/L ≥60 ml/min/1.73 m² 20 mg daily
4.9-5.5 mmol/L Any Do not initiate
>5.5 mmol/L Any Contraindicated

Monitoring Protocol 1:

  1. At 1 month after initiation:

    • Check potassium, creatinine, eGFR
    • If K+ ≤4.8 mmol/L and started on 10 mg: increase to 20 mg daily
    • If K+ 4.9-5.5 mmol/L: continue current dose, recheck in 2 weeks
    • If K+ >5.5 mmol/L: hold finerenone, address hyperkalemia
  2. Every 4 months thereafter:

    • Monitor potassium, creatinine, eGFR
    • Continue if K+ ≤5.5 mmol/L
    • Hold if K+ >5.5 mmol/L

Managing Hyperkalemia:

  • K+ 4.9-5.5 mmol/L: Continue finerenone, monitor more frequently
  • K+ >5.5 mmol/L: Hold finerenone, adjust diet/medications, recheck K+
  • Restart at 10 mg daily when K+ ≤5.0 mmol/L 1

Real-World Safety Data

In FIND-CKD, hyperkalemia occurred in 17.0% with finerenone vs 13.3% with placebo, but led to discontinuation in only 1.5% vs 0.1% and hospitalization in 0.9% vs 0.6% 2. A Chinese real-world study showed similar safety with minimal eGFR impact and effective proteinuria reduction 4.

Combination with SGLT2 Inhibitors

Finerenone can be added to SGLT2 inhibitors in non-diabetic CKD 5. A small randomized trial (n=20) demonstrated additive albuminuria reduction when combining dapagliflozin and finerenone, with a 36% overall UACR reduction and acceptable safety profile 5. This mirrors the diabetic CKD data where combination therapy is explicitly mentioned as appropriate 1.

Critical Caveats

This represents off-guideline use. The KDIGO 2024 guidelines do not recommend finerenone for non-diabetic CKD because they were published before FIND-CKD results. The trial data is compelling but represents a single phase 3 study 2.

Glomerular disease subgroup: In patients with glomerular diseases (IgA nephropathy, FSGS, membranous nephropathy), finerenone showed consistent benefit with 0.73 ml/min/1.73 m² per year slower eGFR decline and 42% albuminuria reduction 6.

Expect transient eGFR decline: Real-world data shows initial eGFR dip at 3 months (88.3→82.1 ml/min/1.73 m²) with recovery by 6 months (87.1 ml/min/1.73 m²) 4, similar to RAS inhibitor initiation patterns.

Practical Recommendation

For non-diabetic proteinuric CKD patients already optimized on RAS inhibitors with persistent albuminuria ≥200 mg/g, finerenone represents a reasonable evidence-based option based on FIND-CKD trial data 2, though it remains off-guideline until KDIGO updates its recommendations. Use the dosing and monitoring algorithm above, with particular attention to potassium management. The combination with SGLT2 inhibitors appears safe and potentially additive for proteinuria reduction 5.

Related Questions

What are the recommended doses of finerenone (Firialta) and eplerenone for a male patient with impaired renal function (eGFR 38 ml/min/1.73 m²)?
Is it appropriate to initiate finerenone in a patient with an estimated glomerular filtration rate of 18 mL/min/1.73 m²?
What is the evidence‑based role of finerenone in adult patients with non‑diabetic proteinuric chronic kidney disease (eGFR ≥25 mL/min/1.73 m², albumin‑to‑creatinine ratio >30 mg/g) who are already on maximally tolerated ACE inhibitor or angiotensin‑receptor blocker?
Is finerenone safe to use in a patient on chronic dialysis?
What are the clinical prescribing guidelines for finerenone in adult patients with chronic kidney disease and type 2 diabetes or chronic heart failure, including dosing, monitoring, contraindications, and precautions?
Can a normal early intrauterine pregnancy present with mild spotting and lower abdominal cramping?
How many scoops of Glucerna are needed for two servings when mixed in a single glass of water?
Should short‑acting propranolol be taken on an empty stomach after radioactive iodine therapy, and does extended‑release propranolol require administration with food?
What is the recommended approach to diagnose central nervous system toxoplasmosis in an immunocompromised patient?
What is the recommended approach, according to Philippines guidelines, for managing a patient who develops an allergic reaction to first‑line anti‑tuberculosis drugs?
What is the appropriate emergent evaluation and management for a patient presenting with new‑onset seizures, marked behavioral changes, and acute loss of vision?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.